Evidence map›Paper›PMID 1678856›Full record

ArticleMolecular and cellular biology1991

The amino-terminal 14 amino acids of v-src can functionally replace the extracellular and transmembrane domains of v-erbB.

M McMahon, R C Schatzman, J M Bishop

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Disease specificity of kinase domains: the src-encoded catalytic domain converts erbB into a sarcoma oncogene.Proceedings of the National Academy of Sciences of the United States of America · 1995
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

M McMahonDepartment of Microbiology and Immunology, University of California, San Francisco 94143.
R C Schatzman
J M Bishop
University of California, San Francisco · USCancer Research Institute of the Slovak Academy of Sciences · SK

Funding

RETROVIRUSES AND CANCER GENESR35CA044338 · NCI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI BISHOP, J MICHAEL · 1987 to 2000
$1.8M
NCI NIH HHS CA 44338
6 · The paper itself

Abstract

The retroviral oncogene v-erbB encodes a truncated form of the receptor for epidermal growth factor, an integral membrane protein-tyrosine kinase. By contrast, the oncogene v-src encodes a protein-tyrosine kinase that is a peripheral membrane protein. The morphologies and spectra of cells transformed by these two oncogenes differ. In an effort to identify the functional determinant(s) of these differences, we constructed and tested first deletion mutants of v-erbB and then chimeras between v-src and v-erbB. As reported previously, the absence of any membrane anchorage eliminated transformation by v-erbB. Anchorage of the cytoplasmic kinase domain of v-erbB to membranes with amino-terminal portions of the v-src protein permitted transformation. The phenotype and spectrum of transformation were those expected for v-erbB rather than for v-src. The transforming chimeras lost their biological activity if the signal for myristylation at the amino terminus of v-src was compromised by mutation. Biochemical fractionations revealed a correlation between transforming activity and the association of chimeric gene products with the membrane fraction of the cell. For reasons not yet apparent, the combined presence of membrane anchorage domains of v-src, and the transmembrane domain of v-erbB in the same chimera typically (but not inevitably) impeded transformation. Our results suggest that the specificity of transformation by v-erbB resides in the selection of substrates by the cytoplasmic domain of the gene product. The protein retains access to those substrates even when anchored to the membrane in the manner of a peripheral rather than a transmembrane protein.

Indexed as

AllelesAnimalsBlotting, WesternCell FractionationCell LineCells, CulturedCell Transformation, NeoplasticMembrane ProteinsMiceOncogene Protein pp60(v-src)Oncogene Proteins v-erbBRatsRecombinant Fusion ProteinsRetroviridae Proteins, OncogenicMembrane ProteinsOncogene Protein pp60(v-src)Oncogene Proteins v-erbBRecombinant Fusion ProteinsRetroviridae Proteins, Oncogenic

Identifiers

PMID1678856
PMCPMC361376
OpenAlexW1860945335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.